Lupin Arm Expands Dabhasa Facility to Boost Peptide Manufacturing Capacity

Lupin Manufacturing Solutions, a subsidiary of Lupin, has announced a strategic expansion of its manufacturing facility at Dabhasa, India, aimed at strengthening its CRDMO capabilities and scaling its peptide platform, the company said in a press release.

The expansion includes a new block to enhance existing infrastructure, along with additional specialised units and increased peptide manufacturing capacity, the release said. The company said the upgrade will support advanced development and flexible manufacturing, catering to complex therapeutics and rising global demand.

The move comes as drug development increasingly shifts towards complex modalities such as peptides and biologic antibody-drug conjugates. With this, the company expects to strengthen its ability to supply high-quality peptide building blocks, including protected amino acids.